logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

Clinical trials, key to developing new drugs and valuable for the economy and cost savings health

Source: www.farmaindustria.es

Each new drug that reaches patients has one behind or, in general, several successful clinical trials. The clinical trial, which in the vast majority of cases (eight out of ten in Spain) is driven by the pharmaceutical industry, represents the final stage of this complex, prolonged and risky background race that involves the R & D of the new medication, which begins when it identifies a promising first compound, in the preclinical stage, and ends 10-12 years later, when, if all went well, the new drug is made available to patients.

Even with the high risk of failure (only one in 10,000 investigated molecules becomes an approved medicine), the entire path of biomedical R & D, and especially the clinical trial, represents a collective and multidisciplinary effort that barely it is comparable with any other action that is carried out today in developed societies.

The clinical trial is one of the best examples of how joining forces with the same goal, which is to achieve new drugs to improve the health of people, sectors and very diverse agents are able to generate a virtuous dynamic that benefits the whole of society, although these benefits are, at times, little known.

Thus, researchers from different fields, health professionals (and especially doctors), managers of health and research centers, responsible for health administrations, professionals of pharmaceutical companies and members of patient organizations have their role in the clinical research of new treatments, and all of them are coparticipants of the collective success that the generation of new scientific knowledge and new therapies entails for the benefit of patients.

But the enormous contributions to the health of the new treatments, which in days like this May 20, World Clinical Trial Day, are generally the most well-known aspect of pharmaceutical innovation, should not eclipse other benefits that for the economy and The productive tissue and R & D of the countries have clinical trials. As noted by John Corea, vice president of Phrma, the association of the innovative pharmaceutical industry in the United States, “clinical trials promoted by the pharmaceutical industry are not only vital to develop new treatments for patients, but also play an important role in the time to promote the economic development of the communities where they are developed “.

The American business association itself recently released a report that reveals how the investment that companies make in clinical trials translates into three times more economic activity. Specifically, the study highlights how the 15,000 million dollars invested by pharmaceutical companies in clinical trials in the United States in 2017 had an overall positive economic impact (summing the indirect economic effects) of about 43,000 million, almost triple.

The figure, which starts from the analysis of the 4,500 clinical trials promoted by the industry in the United States, in which one million patients participated, refers only to direct investments in the centers where clinical trials are carried out, not including those related to design of the trials, data analysis, coordination between different agents or the enormous efforts made in preclinical research (in vitro experimentation and animal models), so that there is no doubt that, counting all the variables, the effect of Generation of wealth would be much greater.

Another key economic effect, which contributes to the increase in the care resources that hospitals make available to their patients, is the cost savings that clinical trials promoted by the pharmaceutical industry generate in the health centers where they are developed. A good example of this reality, also little known outside of the healthcare field, are the clinical trials conducted in Spain.

Thus, in the last 10 years several studies have been published, mostly prepared by the pharmacy services of the hospitals themselves, which reflect this reality and quantify the cost avoided for the center by conducting clinical trials in their facilities. Specifically, they calculate the economic amount of the drugs that the patients included in the trials should have received according to the protocol and that the hospital did not have to pay, since it is the promoter of the trial (a pharmaceutical company in more than 80% of the cases) that finances both those treatments and the investigational drugs. The studies do not include the concomitant medication or other expenses associated with the treatment (personnel, material, etc.), which are also borne by the trial promoter and which increase the pot

Related entries

13 May, 2025

Farmaindustria presents improvements to the Medicines Bill to prepare healthcare for innovation over the next 20 years


Leer más
12 May, 2025

Fina Lladós: ‘We have before us a unique opportunity in these legislative developments to transform our healthcare and prepare it for the next 20 years’.


Leer más
8 May, 2025

Spain, a European success story in clinical trials of new drugs


Leer más

Recent Posts

  • Farmaindustria presents improvements to the Medicines Bill to prepare healthcare for innovation over the next 20 years
  • Fina Lladós: ‘We have before us a unique opportunity in these legislative developments to transform our healthcare and prepare it for the next 20 years’.
  • Spain, a European success story in clinical trials of new drugs
  • Joint position on the draft Medicines and Medical Devices Law
  • The global pharmaceutical industry had 12,700 drugs in development by 2024

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

MADRID DELEGATION

+34 674 575 115
28010 Madrid

Links of interest

  • Legal warning
  • Privacy policy
  • Cookies policy
  • Contact

© 2025 Distefar del Sur SL. All rights reserved. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.